Alleviation of doxorubicin adverse effects via loading into various drug-delivery systems: a comparative study.

IF 3 Q2 PHARMACOLOGY & PHARMACY

Therapeutic delivery Pub Date : 2024-04-19 DOI:10.4155/tde-2023-0121

Rehab M. Abdel-Megeed, Hassan Z Ghanem, Mai O. Kadry

引用次数: 0

Abstract

Aim: Drug resistance is still a significant barrier to effective hepatocellular carcinoma therapy. Address the issue of doxorubicin resistance and inter-receptor crosstalk various doxorubicin formulations were investigated. Methods: Hepatocellular carcinoma was carried out using 3-methylechloroanthrene. Animals were then treated with doxorubicin, liposomal doxorubicin, titanium-loaded doxorubicin (TiO2-Dox), lactoferrin-doxorubicin and PEGylated doxorubicin. Biochemical and molecular analyses were assessed. Results: Results have declared a significant alternation of both sodium and potassium concentrations upon 3-methylechloroanthrene administration. Arginase-I and α-L-Fucodinase tumor biomarkers were significantly elevated. C-myc, Hprt-1 and EGFR gene expression were over-expressed. Treatment with the aforementioned treatment regimens significantly modulated all measured parameters. Conclusion: TiO2-Dox, doxorubicin-lactoferrin and PEGylated doxorubicin could be a promising regimen in hepatocellular carcinoma and overcoming the problem of drug resistance.

查看原文本刊更多论文

通过加入各种给药系统减轻多柔比星的不良反应：一项比较研究。

目的：耐药性仍然是有效治疗肝细胞癌的一大障碍。为解决多柔比星耐药性和受体间串扰问题，研究了多种多柔比星制剂。方法：使用 3-甲基氯蒽治疗肝癌。然后用多柔比星、脂质体多柔比星、钛载多柔比星（TiO2-Dox）、乳铁蛋白-多柔比星和聚乙二醇化多柔比星治疗动物。对生化和分子分析进行了评估。结果结果表明，服用 3-甲基氯蒽后，钠和钾的浓度都发生了明显的变化。精氨酸酶-I和α-L-岩藻糖苷酶肿瘤生物标志物明显升高。C-myc、Hprt-1 和表皮生长因子受体基因表达过度。使用上述治疗方案可明显调节所有测量参数。结论TiO2-Dox、多柔比星-乳铁蛋白和PEG化多柔比星是治疗肝细胞癌和克服耐药性问题的有效方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.50

自引率

0.00%

发文量

期刊介绍： Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.